Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer
Eisai Co., Ltd.
In this trial, participants will be randomised into one of two arms; the experimental arm or the active comparator. In the experimental arm, patients will receive pembrolizumab 200 milligram (mg) intravenously on Day 1 of each 21-day cycle and lenvatinib 20mg orally once daily during each 21-day cycle, for up to 35 cycles. In the active comparator arm, patients will either receive doxorubicin 60 mg/m^2 intravenously on Day 1 of each 21-day cycle for up to a maximum cumulative dose of 500 mg/m^2 OR paclitaxel 80 mg/m^2 intravenously on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.